January 19, 2013
With the newly created AbbVie (NYSE: ABBV ) drawing so much of its revenue from a single source, many investors are worried about what the company will look like after January 2017, when Humira goes over its patent cliff. In this video, Motley Fool health-care bureau chief Brenton Flynn discusses AbbVie's dividend and whether it can really continue to grow. In particular, he explains why strong cash flow for the company over the next few years could very likely mean dividend growth.
In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand new premium report on the company answers the high-profile questions that AbbVie investors are asking, and as an added bonus, you'll receive a full year of free analyst updates as significant news hits. Simply click here now to claim your copy today.